SCHEDULE: BlackRock Discloses Arcutis Biotherapeutics Stake
Beneficial Ownership Filing
BlackRock, Inc. has filed an updated Schedule 13G, reporting a 14.1% beneficial ownership of Arcutis Biotherapeutics Inc. common stock as of September 30, 2026.
Summary
- BlackRock, Inc. has filed an amendment to its Schedule 13G filing.
- The filing reports beneficial ownership of Arcutis Biotherapeutics Inc. common stock.
- As of September 30, 2026, BlackRock beneficially owned 17,751,435 shares, representing 14.1% of the class.
- This ownership includes sole voting power over 17,576,492 shares and sole dispositive power over 17,751,435 shares.
- The filing clarifies that the ownership is held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership, with no new financial or strategic information.
Positives
- BlackRock, a significant institutional investor, maintains a substantial stake in Arcutis Biotherapeutics.
- The filing confirms that the securities are held in the ordinary course of business, suggesting stable, long-term investment rather than activist intent.
Negatives
- The filing does not provide any new financial performance data or strategic updates for Arcutis Biotherapeutics.
Risks
- The primary risk is the potential for BlackRock to significantly alter its holdings, which could impact Arcutis Biotherapeutics' stock price.
- As a large shareholder, BlackRock's investment decisions could be influenced by broader market conditions or changes in its own investment strategies.
Future Outlook
The filing itself does not contain forward-looking statements or guidance for Arcutis Biotherapeutics. It is an update on beneficial ownership.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine for large institutional investors like BlackRock. This filing indicates BlackRock's continued significant investment in the biotherapeutics sector, a field characterized by high R&D costs and potential for significant market disruption.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Revocation and Reissuance | BlackRock, Inc. revoked its previous power of attorney dated April 30, 2023, and issued a new one on January 21, 2025, appointing specific individuals to execute compliance filings. | 01/21/2025 | Ensures continued compliance with reporting requirements by delegating authority to specific personnel. |
Stakeholder Impact
- Shareholders: The filing confirms a significant institutional investor's stake, which can provide a degree of stability but also indicates potential for large trades that could affect share price.
- Management of Arcutis Biotherapeutics: The filing reassures management that BlackRock's current holdings are not for activist purposes, allowing for continued focus on business operations.
Next Steps
- BlackRock will continue to monitor its holdings and may file amendments to this Schedule 13G if its beneficial ownership changes significantly.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous Power of Attorney dated for BlackRock, Inc. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 09/30/2026 | Date of event requiring filing of this statement (ownership as of this date). |
| 10/05/2026 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Arcutis Biotherapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.